New Drug NAV-240 Offers Hope for Hidradenitis Suppurativa Patients

A new experimental drug, NAV-240, is being tested in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. The drug targets two inflammatory pathways, TNF and OX40 ligand, which are known to drive inflammation in HS. By blocking both TNF, a well-known driver of inflammation, and OX40 ligand, which activates immune cells that perpetuate inflammation, NAV-240 aims to provide a more wide-ranging approach to treatment.

According to the report, the FDA has cleared a phase 2a trial of NAV-240, and Navigator Medicines has begun dosing patients. The drug’s dual-target approach aims to provide more effective relief than existing treatments, which often fail to deliver lasting results. This strategy is particularly promising for patients who have not responded adequately to current biologics, which typically target only TNF.

Early testing in 40 healthy volunteers showed that NAV-240 was generally well-tolerated, with no serious side effects. Researchers observed a drop in TARC, a blood marker associated with inflammatory skin diseases, indicating the drug’s potential to reduce inflammation. The phase 1 study also demonstrated dose-proportional increases in drug levels, aiding in the planning of subsequent trials. Additionally, a separate study involving repeated doses in 24 healthy volunteers confirmed the drug’s safety and showed dose-dependent reductions in inflammatory markers, further supporting its biological activity.

Read Also: Cream shows promise for hidradenitis suppurativa treatment

For individuals with HS who haven’t found lasting relief from current biologics, this new approach may offer hope. However, larger and longer studies are needed to confirm its effectiveness. The phase 2a trial results are expected in the second half of 2027, providing critical data on whether the dual-target approach translates into clinical benefits for HS patients.

In addition to NAV-240, Navigator Medicines is developing a longer-lasting version, NAV-242, which could require less frequent dosing. Its first human study is underway, evaluating safety and pharmacokinetics, with initial results anticipated in late 2026. This extended-duration formulation aims to improve patient convenience and adherence, addressing a key limitation of current treatments.